THE STRUCTURE AND EFFICACY OF B-CELL LYMPHOMA'S REAL LIFE TREATMENT ACCORDING DATA OF THE REGIONAL SEGMENT OF THE RUSSIAN FEDERATION'S FEDERAL REGISTER
(Abstract release date: 05/19/16)
EHA Library. Volkova S. 06/09/16; 134777; PB1877
Dr. Svetlana Volkova
Contributions
Contributions
Abstract
Abstract: PB1877
Type: Publication Only
Background
The Russian federal program of '7 nosology' since 2008 has given the chance of stable treatment CD20+ B cell lymphoma patients with rituximab, B cell chronic lymphoid leukemia patients with rituximab and fludarabin and multiple myeloma (MM) patients with bortezomib in combination with conventional chemotherapy. The obtaining medications provide patient's inclusion in the federal register and exception from the register in case of death and other actions.
Aims
To analyze the federal register's regional segment of the of patients with B-cell mature lymphomas, residents of the Nizhny Novgorod Region of RF (Population of the Nizhny Novgorod Region in 2008 of-3359,8 thousand and in 2015 – 3164,2 thousand people) for receiving demographic data and efficacy of real life treatment with using rituximab without or with fludarabin and conventional chemotherapy on the basis of overall survival (OS) by Kaplana-Meyer's method.
Methods
Materials and methods: from Jan 2008 to Dec 2015 2094 patients are allocated, the analysis has included 2051(98%) with diagnoses: C82 Follicular lymphoma – 103 (5%), C83.0 – Lymphoma from small lymphocytes, Nodal marginal zone lymphoma, Lymphoplasmacytic lymphoma (excepting Waldenstrom macroglobulinemia) – 183 (9%), C83.1 – Mantle cell lymphoma -46 (2%), C83.3 – Diffuse large B-cell lymphoma (all variants) – 532 (26%), C91.1 – Chronic lymphocytic leukemia – 578 (28%), C90 – multiple myeloma - 609 (30%). Date of death is determined in 713 (35%) cases, other censored for date of the last data in the register. The OS of patients is defined from the date of inclusion in the program of 7 nosology. In the groups the OS is defined depending on a sex, age group with the step in 10 years, of a year of inclusion in the program of 7 nosology. To analyze the Excel and Statistica 9 software are used.
Results
The probability of OS from the moment of inclusion in the register within 12 months for patients with C82 was 87%, C83.0 - 84%, C83.1 - 67%, C83.3 - 77%, C91.1 - 86%. The probability of OS for patients with C82 till 96 months is 72%, C 83.0 till 93 months – 29%, C 83.1 till 34 months – 59%, C 83.3 till 96 months - 61%, C 91.1 till 96 months - 45%, (Chi-square = 23,2, p = 0,0001). In groups except C91.1 women prevailed, distinctions of OS according sex aren't received. Only in the group C 91.1 men (315) prevailed (women 154), the median of OS for women isn't reached, for men – 62 months (р <0,003). Depending on age with a step in 10 years in all groups distinctions in OS aren't received. The maximum number of patients with the diagnosis C82, C83.1, C83.3, C91.1 were in age 60-69 years, with the diagnosis C83.0 – in age 50-59 years. Only patients with the diagnosis C83.3 are registered in all age groups. During 2009-2015 the number of the patients included in the register in a year with diagnoses of C82 has made from 7 to 24, on average 13; C83.3 – from 32 to 96, on average 68, C91.1 – from 30 to 83, on average 63; C83.0 – from 16 to 27, on average 21, C 83.1 from 1 to 15, on average 9. In each group of distinctions of survival depending on a year of inclusion in the program of 7 nosology it isn't received.
Conclusion
The rituximab for all CD20+ lymphomas and fludarabin + rituximab for BCLL improve the outcome patients in real life clinical practice. The register interacted to the mechanism of the provision of medication is the effective resource allowing to have demographic data and data on efficacy treatment in real life medical practice.
Session topic: E-poster
Keyword(s): B cell lymphoma, Rituximab
Type: Publication Only
Background
The Russian federal program of '7 nosology' since 2008 has given the chance of stable treatment CD20+ B cell lymphoma patients with rituximab, B cell chronic lymphoid leukemia patients with rituximab and fludarabin and multiple myeloma (MM) patients with bortezomib in combination with conventional chemotherapy. The obtaining medications provide patient's inclusion in the federal register and exception from the register in case of death and other actions.
Aims
To analyze the federal register's regional segment of the of patients with B-cell mature lymphomas, residents of the Nizhny Novgorod Region of RF (Population of the Nizhny Novgorod Region in 2008 of-3359,8 thousand and in 2015 – 3164,2 thousand people) for receiving demographic data and efficacy of real life treatment with using rituximab without or with fludarabin and conventional chemotherapy on the basis of overall survival (OS) by Kaplana-Meyer's method.
Methods
Materials and methods: from Jan 2008 to Dec 2015 2094 patients are allocated, the analysis has included 2051(98%) with diagnoses: C82 Follicular lymphoma – 103 (5%), C83.0 – Lymphoma from small lymphocytes, Nodal marginal zone lymphoma, Lymphoplasmacytic lymphoma (excepting Waldenstrom macroglobulinemia) – 183 (9%), C83.1 – Mantle cell lymphoma -46 (2%), C83.3 – Diffuse large B-cell lymphoma (all variants) – 532 (26%), C91.1 – Chronic lymphocytic leukemia – 578 (28%), C90 – multiple myeloma - 609 (30%). Date of death is determined in 713 (35%) cases, other censored for date of the last data in the register. The OS of patients is defined from the date of inclusion in the program of 7 nosology. In the groups the OS is defined depending on a sex, age group with the step in 10 years, of a year of inclusion in the program of 7 nosology. To analyze the Excel and Statistica 9 software are used.
Results
The probability of OS from the moment of inclusion in the register within 12 months for patients with C82 was 87%, C83.0 - 84%, C83.1 - 67%, C83.3 - 77%, C91.1 - 86%. The probability of OS for patients with C82 till 96 months is 72%, C 83.0 till 93 months – 29%, C 83.1 till 34 months – 59%, C 83.3 till 96 months - 61%, C 91.1 till 96 months - 45%, (Chi-square = 23,2, p = 0,0001). In groups except C91.1 women prevailed, distinctions of OS according sex aren't received. Only in the group C 91.1 men (315) prevailed (women 154), the median of OS for women isn't reached, for men – 62 months (р <0,003). Depending on age with a step in 10 years in all groups distinctions in OS aren't received. The maximum number of patients with the diagnosis C82, C83.1, C83.3, C91.1 were in age 60-69 years, with the diagnosis C83.0 – in age 50-59 years. Only patients with the diagnosis C83.3 are registered in all age groups. During 2009-2015 the number of the patients included in the register in a year with diagnoses of C82 has made from 7 to 24, on average 13; C83.3 – from 32 to 96, on average 68, C91.1 – from 30 to 83, on average 63; C83.0 – from 16 to 27, on average 21, C 83.1 from 1 to 15, on average 9. In each group of distinctions of survival depending on a year of inclusion in the program of 7 nosology it isn't received.
Conclusion
The rituximab for all CD20+ lymphomas and fludarabin + rituximab for BCLL improve the outcome patients in real life clinical practice. The register interacted to the mechanism of the provision of medication is the effective resource allowing to have demographic data and data on efficacy treatment in real life medical practice.
Session topic: E-poster
Keyword(s): B cell lymphoma, Rituximab
Abstract: PB1877
Type: Publication Only
Background
The Russian federal program of '7 nosology' since 2008 has given the chance of stable treatment CD20+ B cell lymphoma patients with rituximab, B cell chronic lymphoid leukemia patients with rituximab and fludarabin and multiple myeloma (MM) patients with bortezomib in combination with conventional chemotherapy. The obtaining medications provide patient's inclusion in the federal register and exception from the register in case of death and other actions.
Aims
To analyze the federal register's regional segment of the of patients with B-cell mature lymphomas, residents of the Nizhny Novgorod Region of RF (Population of the Nizhny Novgorod Region in 2008 of-3359,8 thousand and in 2015 – 3164,2 thousand people) for receiving demographic data and efficacy of real life treatment with using rituximab without or with fludarabin and conventional chemotherapy on the basis of overall survival (OS) by Kaplana-Meyer's method.
Methods
Materials and methods: from Jan 2008 to Dec 2015 2094 patients are allocated, the analysis has included 2051(98%) with diagnoses: C82 Follicular lymphoma – 103 (5%), C83.0 – Lymphoma from small lymphocytes, Nodal marginal zone lymphoma, Lymphoplasmacytic lymphoma (excepting Waldenstrom macroglobulinemia) – 183 (9%), C83.1 – Mantle cell lymphoma -46 (2%), C83.3 – Diffuse large B-cell lymphoma (all variants) – 532 (26%), C91.1 – Chronic lymphocytic leukemia – 578 (28%), C90 – multiple myeloma - 609 (30%). Date of death is determined in 713 (35%) cases, other censored for date of the last data in the register. The OS of patients is defined from the date of inclusion in the program of 7 nosology. In the groups the OS is defined depending on a sex, age group with the step in 10 years, of a year of inclusion in the program of 7 nosology. To analyze the Excel and Statistica 9 software are used.
Results
The probability of OS from the moment of inclusion in the register within 12 months for patients with C82 was 87%, C83.0 - 84%, C83.1 - 67%, C83.3 - 77%, C91.1 - 86%. The probability of OS for patients with C82 till 96 months is 72%, C 83.0 till 93 months – 29%, C 83.1 till 34 months – 59%, C 83.3 till 96 months - 61%, C 91.1 till 96 months - 45%, (Chi-square = 23,2, p = 0,0001). In groups except C91.1 women prevailed, distinctions of OS according sex aren't received. Only in the group C 91.1 men (315) prevailed (women 154), the median of OS for women isn't reached, for men – 62 months (р <0,003). Depending on age with a step in 10 years in all groups distinctions in OS aren't received. The maximum number of patients with the diagnosis C82, C83.1, C83.3, C91.1 were in age 60-69 years, with the diagnosis C83.0 – in age 50-59 years. Only patients with the diagnosis C83.3 are registered in all age groups. During 2009-2015 the number of the patients included in the register in a year with diagnoses of C82 has made from 7 to 24, on average 13; C83.3 – from 32 to 96, on average 68, C91.1 – from 30 to 83, on average 63; C83.0 – from 16 to 27, on average 21, C 83.1 from 1 to 15, on average 9. In each group of distinctions of survival depending on a year of inclusion in the program of 7 nosology it isn't received.
Conclusion
The rituximab for all CD20+ lymphomas and fludarabin + rituximab for BCLL improve the outcome patients in real life clinical practice. The register interacted to the mechanism of the provision of medication is the effective resource allowing to have demographic data and data on efficacy treatment in real life medical practice.
Session topic: E-poster
Keyword(s): B cell lymphoma, Rituximab
Type: Publication Only
Background
The Russian federal program of '7 nosology' since 2008 has given the chance of stable treatment CD20+ B cell lymphoma patients with rituximab, B cell chronic lymphoid leukemia patients with rituximab and fludarabin and multiple myeloma (MM) patients with bortezomib in combination with conventional chemotherapy. The obtaining medications provide patient's inclusion in the federal register and exception from the register in case of death and other actions.
Aims
To analyze the federal register's regional segment of the of patients with B-cell mature lymphomas, residents of the Nizhny Novgorod Region of RF (Population of the Nizhny Novgorod Region in 2008 of-3359,8 thousand and in 2015 – 3164,2 thousand people) for receiving demographic data and efficacy of real life treatment with using rituximab without or with fludarabin and conventional chemotherapy on the basis of overall survival (OS) by Kaplana-Meyer's method.
Methods
Materials and methods: from Jan 2008 to Dec 2015 2094 patients are allocated, the analysis has included 2051(98%) with diagnoses: C82 Follicular lymphoma – 103 (5%), C83.0 – Lymphoma from small lymphocytes, Nodal marginal zone lymphoma, Lymphoplasmacytic lymphoma (excepting Waldenstrom macroglobulinemia) – 183 (9%), C83.1 – Mantle cell lymphoma -46 (2%), C83.3 – Diffuse large B-cell lymphoma (all variants) – 532 (26%), C91.1 – Chronic lymphocytic leukemia – 578 (28%), C90 – multiple myeloma - 609 (30%). Date of death is determined in 713 (35%) cases, other censored for date of the last data in the register. The OS of patients is defined from the date of inclusion in the program of 7 nosology. In the groups the OS is defined depending on a sex, age group with the step in 10 years, of a year of inclusion in the program of 7 nosology. To analyze the Excel and Statistica 9 software are used.
Results
The probability of OS from the moment of inclusion in the register within 12 months for patients with C82 was 87%, C83.0 - 84%, C83.1 - 67%, C83.3 - 77%, C91.1 - 86%. The probability of OS for patients with C82 till 96 months is 72%, C 83.0 till 93 months – 29%, C 83.1 till 34 months – 59%, C 83.3 till 96 months - 61%, C 91.1 till 96 months - 45%, (Chi-square = 23,2, p = 0,0001). In groups except C91.1 women prevailed, distinctions of OS according sex aren't received. Only in the group C 91.1 men (315) prevailed (women 154), the median of OS for women isn't reached, for men – 62 months (р <0,003). Depending on age with a step in 10 years in all groups distinctions in OS aren't received. The maximum number of patients with the diagnosis C82, C83.1, C83.3, C91.1 were in age 60-69 years, with the diagnosis C83.0 – in age 50-59 years. Only patients with the diagnosis C83.3 are registered in all age groups. During 2009-2015 the number of the patients included in the register in a year with diagnoses of C82 has made from 7 to 24, on average 13; C83.3 – from 32 to 96, on average 68, C91.1 – from 30 to 83, on average 63; C83.0 – from 16 to 27, on average 21, C 83.1 from 1 to 15, on average 9. In each group of distinctions of survival depending on a year of inclusion in the program of 7 nosology it isn't received.
Conclusion
The rituximab for all CD20+ lymphomas and fludarabin + rituximab for BCLL improve the outcome patients in real life clinical practice. The register interacted to the mechanism of the provision of medication is the effective resource allowing to have demographic data and data on efficacy treatment in real life medical practice.
Session topic: E-poster
Keyword(s): B cell lymphoma, Rituximab
{{ help_message }}
{{filter}}